30.11.2015 - Recently founded UK-based speciality biopharmaceutical company Mereo Biopharmaceuticals has brought in Paul Blackburn to take over as Non-executive Board Director and Chairman of the Audit.
Blackburn is currently Senior VP Strategic Finance Projects at GlaxoSmithKline. He previously held senior finance executive positions at GSK and recently served on the GSK Audit and Risk Committee. He is also a Non-Executive Director of Syngene International and a member of Syngene's Audit and Risk Committee and Stakeholder Relationships Committee. He holds a BSc in Management Sciences from Warwick University and also a professional accounting qualification from the Chartered Institute of Management Accountants.
In parallel to Blackburn’s addition to the Board, Mereo has also appointed Anthony Hall as Head of Orphan Diseases, Jacqueline Parkin as Head of Respiratory and Endocrinology, Fiona Bor: Head of Intellectual Property and Ian Hodgson: Head of Clinical Operations.http://www.european-biotechnology-news.com/people/bio-people/2015/paul-blackburn.html